Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNIPR001
- Development stage
- Phase 2
- Lead developer
- SNIPR Biome
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intralesional, Intravenous, Oral, Topical
01
Overview
**SNIPR001** is an investigational precision antimicrobial developed by SNIPR Biome. It is a cocktail of four engineered CRISPR-Cas-armed bacteriophages designed to selectively infect and eliminate *Escherichia coli* in the gastrointestinal tract while minimizing disruption of commensal microbiota. The oral program is in Phase 1b/2a development for prevention of fluoroquinolone-resistant *E. coli* bloodstream infections in patients with hematologic malignancies undergoing allogeneic hematopoietic stem-cell transplantation and receiving fluoroquinolone prophylaxis. A completed first-in-human Phase 1 study in healthy participants supported oral safety, tolerability, gastrointestinal restriction, and pharmacodynamic reduction of targeted *E. coli* colonization. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41785880/))
- Other names
- SNIPR 001SNIPR001SNIPR-001
02
Targets
bacterial dsDNA (Bacterial double-stranded DNA)
Beyond the preview
Go deeper on SNIPR001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNIPR001.